MedTrace Logo

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

NCT00002532 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-08-07

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed or refractory acute lymphocytic leukemia.

Conditions

Interventions

BIOLOGICAL

filgrastim

DRUG

asparaginase

DRUG

cytarabine

DRUG

daunorubicin hydrochloride

DRUG

dexamethasone

DRUG

etoposide

DRUG

idarubicin

DRUG

ifosfamide

DRUG

leucovorin calcium

DRUG

methotrexate

DRUG

prednisolone

DRUG

vindesine

Sponsors & Collaborators

  • Hannover Medical School

    lead OTHER

Principal Investigators

  • Mathias Freund, MD · Klinik und Poliklinik fuer Innere Medizin - Universitaet Rostock

Study Design

Purpose
TREATMENT

Eligibility

Min Age
15 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002532 on ClinicalTrials.gov